02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
16:35 , Dec 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Mouse and cell culture studies suggest promoting the expression of SRXN1 , which denitrosylates PRDX2 , could help treat PD. In brain tissue samples from a model of chemical-induced PD, levels...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxiredoxin 6 (PRDX6); microRNA 371-3p (miR-371-3p)

Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest promoting expression of miR-371-3p or inhibiting PRDX6 could help treat Tarceva erlotinib-resistant lung and other cancers. In patients with lung, colorectal, gastric or...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Peroxiredoxin 2 (PRDX2) Mouse studies suggest compounds that mimic PRDX2 activity could help prevent melanoma metastasis. In mice, melanoma cells pretreated with Prx2-targeting small...
07:00 , May 7, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer HER2 (ERBB2; neu); peroxiredoxin 1 (PRDX1); phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1) A study in...